News and Trends 11 May 2021
ADC Approval Buoys Spirits in Cancer Treatment Space
The FDA recently approved an antibody-drug conjugate drug from ADC Therapeutics as a treatment for blood cancer. This has given…
MSD
- Latest Posts
News and Trends 28 May 2020
MSD Enters Covid-19 Vaccine Race by Acquiring Themis Bioscience
The US-based big pharma MSD has entered the race to be the first to develop an effective vaccine for Covid-19…
News and Trends 22 Aug 2019
Austrian Vaccine Developer Signs Deal with MSD in ‘Blockbuster Indication’
Vienna-based Themis Bioscience will develop vaccine candidates against an undisclosed disease target in partnership with big pharma Merck Sharp &…
In Depth 9 Apr 2018
Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought?
Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much of it is hype? The…
ADVERTISEMENT
News and Trends 6 Sep 2017
MSD Offers €464M to Buy German Biotech Fighting Cancer with RNA
MSD is back in the RNA field with the acquisition of Rigontec, a German biotech harnessing RNA interference to make…
News and Trends 12 Jun 2017
German Biotech Unveils Positive Phase II Results for Alzheimer’s
Probiodrug has disclosed encouraging results of its latest Phase IIa trial to assess its lead candidate PQ912 in patients with…
News and Trends 16 May 2017
Berlin Biotech Advances its Cancer Drug in a New Trial with Keytruda
Noxxon Pharma has teamed up with the NCT in Heidelberg to conduct a Phase I/II trial combining its lead NOX-A12…
News and Trends 28 Oct 2016
TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer
Adaptimmune and MSD are collaborating to test a therapy for multiple myeloma that combines some of the most promising technologies…
News and Trends 22 Aug 2016
UPDATE: Sanofi defeated in the Race to acquire Medivation
Even more Big Pharma join the fight to acquire the extremely desirable Medivation, a Biotech developing cancer treatments. Now MSD is joining the…
News and Trends 28 Jun 2016
And now, Immuno-oncology gets EMA’s pre-approval for Lung Cancer
MSD has received EMA pre-approval for its famous anti-PD-1 therapy, Keytruda. It could soon be used to treat non-small cell…
ADVERTISEMENT
News and Trends 15 Mar 2016
How will the UK’s Potential Exit from the EU Affect the Biotech Industry?
I'm a UK Expat in Berlin, and whilst I admit confusion over where exactly the British Exit (i.e. "Brexit") will…
News and Trends 1 Feb 2016
New Discovery unites Australia, Germany and UK Against Blood Cancers
Cancer Research UK has teamed up with MSD (Merck) and the Wellcome Trust to co-develop some Inhibitors for both Cancerous and…
News and Trends 26 Jan 2016
Keytruda Combo! MSD Recruits German Biotech on Lymphoma PD-1 Trial
Affimed in Heidelberg (Germany) will fund and conduct a clinical trial to investigate the combination of Merck's (MSD) anti-PD-1 therapy (Keytruda),…
News and Trends 7 Jan 2016
Alphabody Platform for Cancer Draws in €260M Discovery Deal with MSD
Complix is a Belgian Immuno-Oncology Biotech with a proprietary Alphabody platform, which has now attracted a €260M strategic drug discovery…
News and Trends 14 Dec 2015
Red Blood Cells to Carry Drugs? A US Start-Up Inspired by French Biotech to Focus on Rare Metabolic Disease
Erytech (France) is working on a drug-transportation system using red blood cells. Now US Rubius Therapeutics joins Erytech on this…
News and Trends 8 Dec 2015
Merck Pulls out of Plans to Commercialize Cancer Drug After it Fails in Two Phase III Trials
Threshold Pharmaceuticals in the US has failed at getting its hypoxia prodrug evofosfamide through phase III trials for two types…
ADVERTISEMENT
News and Trends 15 Oct 2015
Ablynx richly rewarded for MSD’s Nanobody Proof in Immuno-Oncology
Ablynx - the Belgian nanobody biotech (which uses monoclonal antibodies of Alpacas), has now achieved it's first pre-clinical milestone in…
News and Trends 15 Oct 2015
Neurodegenerative Disease in the UK: Takeda, NIHR & UCL Research Collaboration
Takeda Cambridge (the UK subsidiary of global biotech Takeda Pharmaceuticals) will now collaborate with University College London's Institute for Neurology…
News and Trends 10 Oct 2015
What Happened this Week? Nobel prize slips through CRISPR’s fingers, inside iGEM’s Jamboree and €120M boost for Alzheimer’s research
Monday: Manfred Horst on MSD, Biosimilars, KEYTRUDA and Merck & Co.’s rich history Tuesday: An Insider’s experience at the iGEM Giant Boston…
News and Trends 8 Oct 2015
Rabbit Antibodies proven to be more specific than Mice in Immuno-oncology PD-L1 Research
Abcam is a Cambridge (UK) Biotech who have developed a monoclonal antibody (mAB) production platform from rabbits. This platform is…